Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Moderate to Severe Plaque Psoriasis: full-pipeline trial registry
3 of 4 indexed Moderate to Severe Plaque Psoriasis trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Moderate to Severe Plaque Psoriasis: 4 US clinical trials tracked, 3 recruiting.
Moderate to Severe Plaque Psoriasis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 4 of these trials.
Enrollment posture brief
Registry condition moderate-to-severe-plaque-psoriasis
OPEN 3 | RECR 75% | LATE 2 | EARLY 2 | RANK #4115 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Moderate to Severe Plaque Psoriasis lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Moderate to Severe Plaque Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Moderate to Severe Plaque Psoriasis is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL
NCT06425549
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL
NCT06506916
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
NCT06888193
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL
NCT04718896
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Moderate to Severe Plaque Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Moderate to Severe Plaque Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Moderate to Severe Plaque Psoriasis page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Moderate to Severe Plaque Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UCB Biopharma SRL sponsors the most Moderate to Severe Plaque Psoriasis trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderate to Severe Plaque Psoriasis condition card totals 4 registered trials; most-linked intervention bimekizumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.